Trial Outcomes & Findings for Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area (NCT NCT01426373)

NCT ID: NCT01426373

Last Updated: 2016-01-14

Results Overview

Serious AEs include any event that met one or more of the following criteria: was fatal or life-threatening, required inpatient hospitalization or prolonged a hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or a significant medical hazard. The severity of each AE was defined as either: Mild: The participant was aware of the sign or symptom, but it was easily tolerated. Moderate: The sign or symptom caused discomfort and interfered with usual activity. Severe: The sign or symptom was incapacitating, and the participant was unable to engage in usual activity. The investigator determined the relationship of each AE to the study drug using the question: "Is there a reasonable possibility that the event may have been caused by treatment with the study drug?"

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

165 participants

Primary outcome timeframe

Up to 12 months after last treatment (maximum of 18 months from first treatment)

Results posted on

2016-01-14

Participant Flow

The study was conducted at 18 investigational centers in the United States.

Participant milestones

Participant milestones
Measure
Deoxycholic Acid 2 mg/cm²
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
Overall Study
STARTED
165
Overall Study
COMPLETED
131
Overall Study
NOT COMPLETED
34

Reasons for withdrawal

Reasons for withdrawal
Measure
Deoxycholic Acid 2 mg/cm²
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
Overall Study
Adverse Event
6
Overall Study
Lost to Follow-up
14
Overall Study
Participant Convenience
10
Overall Study
Miscellaneous Reasons
4

Baseline Characteristics

Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Deoxycholic Acid 2 mg/cm²
n=165 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
Age, Continuous
46.9 years
STANDARD_DEVIATION 10.89 • n=99 Participants
Age, Customized
18 - 50 years
98 participants
n=99 Participants
Age, Customized
51 - 65 years
63 participants
n=99 Participants
Age, Customized
> 65 years
4 participants
n=99 Participants
Sex: Female, Male
Female
128 Participants
n=99 Participants
Sex: Female, Male
Male
37 Participants
n=99 Participants
Race/Ethnicity, Customized
American Indian or Alaskan Native
1 participants
n=99 Participants
Race/Ethnicity, Customized
Asian
7 participants
n=99 Participants
Race/Ethnicity, Customized
Black or African American
15 participants
n=99 Participants
Race/Ethnicity, Customized
Multiple
1 participants
n=99 Participants
Race/Ethnicity, Customized
Other
12 participants
n=99 Participants
Race/Ethnicity, Customized
White
129 participants
n=99 Participants
Race/Ethnicity, Customized
Hispanic or Latino
30 participants
n=99 Participants
Race/Ethnicity, Customized
Not Hispanic or Latino
135 participants
n=99 Participants
Weight
80.37 kg
STANDARD_DEVIATION 15.111 • n=99 Participants
Body Mass Index (BMI)
28.88 kg/m²
STANDARD_DEVIATION 4.311 • n=99 Participants
Fitzpatrick Skin Type
I - III
123 participants
n=99 Participants
Fitzpatrick Skin Type
IV - VI
42 participants
n=99 Participants
Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) Rating
2
86 participants
n=99 Participants
Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) Rating
3
66 participants
n=99 Participants
Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) Rating
4
13 participants
n=99 Participants

PRIMARY outcome

Timeframe: Up to 12 months after last treatment (maximum of 18 months from first treatment)

Population: Safety population

Serious AEs include any event that met one or more of the following criteria: was fatal or life-threatening, required inpatient hospitalization or prolonged a hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or a significant medical hazard. The severity of each AE was defined as either: Mild: The participant was aware of the sign or symptom, but it was easily tolerated. Moderate: The sign or symptom caused discomfort and interfered with usual activity. Severe: The sign or symptom was incapacitating, and the participant was unable to engage in usual activity. The investigator determined the relationship of each AE to the study drug using the question: "Is there a reasonable possibility that the event may have been caused by treatment with the study drug?"

Outcome measures

Outcome measures
Measure
Deoxycholic Acid 2 mg/cm²
n=165 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
Month 12 After Last Treatment
Number of Participants With Adverse Events (AEs)
Any adverse event
160 participants
Number of Participants With Adverse Events (AEs)
Serious adverse event
7 participants
Number of Participants With Adverse Events (AEs)
Severe adverse event
11 participants
Number of Participants With Adverse Events (AEs)
Adverse event leading to withdrawal from treatment
15 participants
Number of Participants With Adverse Events (AEs)
Adverse event leading to study discontinuation
6 participants
Number of Participants With Adverse Events (AEs)
Adverse event leading to death
1 participants
Number of Participants With Adverse Events (AEs)
Adverse event related to study drug
155 participants
Number of Participants With Adverse Events (AEs)
Serious adverse event related to study drug
0 participants
Number of Participants With Adverse Events (AEs)
Adverse event associated with the treatment area
158 participants

SECONDARY outcome

Timeframe: Baseline and months 3, 6, 9, and 12 after last treatment

Population: Treatment effect population (all participants who received at least 1 injection with study drug and had any posttreatment data for treatment effect variables or for the submental skin laxity grade) and with available data at each time point (indicated by "n").

The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme). A negative change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Deoxycholic Acid 2 mg/cm²
n=165 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
Month 12 After Last Treatment
Mean Change From Baseline in Clinician-Reported Submental Fat Rating Scale Scores (CR-SMFRS)
Month 3 after last treatment (n = 144)
-1.3 units on a scale
Standard Deviation 0.85
Mean Change From Baseline in Clinician-Reported Submental Fat Rating Scale Scores (CR-SMFRS)
Month 6 after last treatment (n = 133)
-1.3 units on a scale
Standard Deviation 0.85
Mean Change From Baseline in Clinician-Reported Submental Fat Rating Scale Scores (CR-SMFRS)
Month 9 after last treatment (n = 134)
-1.4 units on a scale
Standard Deviation 0.81
Mean Change From Baseline in Clinician-Reported Submental Fat Rating Scale Scores (CR-SMFRS)
Month 12 after last treatment (n = 131)
-1.4 units on a scale
Standard Deviation 0.80

SECONDARY outcome

Timeframe: Baseline and month 3 and month 12 after last treatment

Population: Treatment effect population with available data at baseline (163) and at each time point (indicated by "n")

The PR-SMFRS is based on the participant's response to the question "How much fat do you have under your chin right now?" and answered on a 5-point ordinal scale (0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat). A negative change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Deoxycholic Acid 2 mg/cm²
n=163 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
Month 12 After Last Treatment
Mean Change From Baseline in Patient-Reported Submental Fat Scale Rating Scale (PR-SMFRS)
Month 3 after last treatment (n = 142)
-1.2 units on a scale
Standard Deviation 0.90
Mean Change From Baseline in Patient-Reported Submental Fat Scale Rating Scale (PR-SMFRS)
Month 12 after last treatment (n = 127)
-1.3 units on a scale
Standard Deviation 0.88

SECONDARY outcome

Timeframe: Baseline and month 3 and month 12 after last treatment

Population: Treatment effect population with available data at baseline and at each time point (indicated by "n")

A composite 1-grade response is defined as at least a 1-grade improvement from baseline on both the CR-SMFRS and PR-SMFRS. The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme). The PR-SMFRS is based on the participant's response to the question "How much fat do you have under your chin right now?" and answered on a 5-point ordinal scale (0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat).

Outcome measures

Outcome measures
Measure
Deoxycholic Acid 2 mg/cm²
n=163 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
Month 12 After Last Treatment
Percentage of Participants Who Achieved a Composite 1-grade Response
Month 3 after last treatment (n = 142)
72.5 percentage of participants
Percentage of Participants Who Achieved a Composite 1-grade Response
Month 12 after last treatment (n = 128)
75.0 percentage of participants

SECONDARY outcome

Timeframe: Baseline and month 3 and month 12 after last treatment

Population: Treatment effect population with available data at baseline and at each time point (indicated by "n")

A composite 2-grade response is defined as at least a 2-grade improvement from baseline on both the CR-SMFRS and PR-SMFRS. The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme). The PR-SMFRS is based on the participant's response to the question "How much fat do you have under your chin right now?" and answered on a 5-point ordinal scale (0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat).

Outcome measures

Outcome measures
Measure
Deoxycholic Acid 2 mg/cm²
n=163 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
Month 12 After Last Treatment
Percentage of Participants Who Achieved a Composite 2-grade Response
Month 3 after last treatment (n = 142)
14.1 percentage of participants
Percentage of Participants Who Achieved a Composite 2-grade Response
Month 12 after last treatment (n = 128)
20.3 percentage of participants

SECONDARY outcome

Timeframe: Baseline and month 3 and month 12 after last treatment

Population: Treatment effect population with available data at baseline and each time point (indicated by "n")

The PR-SMFIS assesses the impact of submental fat on self-perception of 6 emotional and visual characteristics (unhappy, bothered, self-conscious, embarrassed, look older, and look overweight) related to the appearance of submental fullness as evaluated by the participant. Each item is rated on an 11-point numeric scale from 0 to 10. Scores for the 6 items were averaged to generate a PR-SMFIS total scale score ranging from 0 to 10 where 0 is a positive outcome and 10 is a negative outcome. A negative change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Deoxycholic Acid 2 mg/cm²
n=163 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
Month 12 After Last Treatment
Mean Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)
Month 3 after last treatment (n = 145)
-4.3 units on a scale
Standard Deviation 2.86
Mean Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)
Month 12 after last treatment (n = 129)
-4.2 units on a scale
Standard Deviation 2.86

SECONDARY outcome

Timeframe: Baseline and month 3 and month 12 after last treatment

Population: Treatment effect population with available data (indicated by "n")

The SSRS assesses participants' satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6 (0 = extremely dissatisfied, 1 = dissatisfied, 2 = slightly dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = slightly satisfied, 5 = satisfied and 6 = extremely satisfied). A positive change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Deoxycholic Acid 2 mg/cm²
n=165 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
Month 12 After Last Treatment
Mean Change From Baseline in Subject Self Rating Scale (SSRS)
Month 3 after last treatment (n = 144)
3.6 units on a scale
Standard Deviation 1.49
Mean Change From Baseline in Subject Self Rating Scale (SSRS)
Month 12 after last treatment (n = 128)
3.8 units on a scale
Standard Deviation 1.36

SECONDARY outcome

Timeframe: Baseline and month 3 and month 12 after last treatment

Population: Treatment effect population with available data at baseline (163), month 3 (144), and month 12 (130)

Self-rating of Attractiveness assesses aspects of appearance from the participant's perspective with a series of 6 questions: How attractive do you think your overall appearance (chin/neck, eyes, nose, mouth, entire face) is/are?" Each question was answered on a scale from 1 to 9 (1 = not at all attractive, 5 = neither attractive nor unattractive, and 9 = extremely attractive). A positive change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Deoxycholic Acid 2 mg/cm²
n=163 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
Month 12 After Last Treatment
Mean Change From Baseline in Self-rating of Attractiveness
Overall appearance - month 3 after last treatment
0.8 units on a scale
Standard Deviation 1.53
Mean Change From Baseline in Self-rating of Attractiveness
Overall appearance - month 12 after last treatment
1.0 units on a scale
Standard Deviation 1.62
Mean Change From Baseline in Self-rating of Attractiveness
Chin/neck - month 3 after last treatment
2.6 units on a scale
Standard Deviation 2.35
Mean Change From Baseline in Self-rating of Attractiveness
Chin/neck - month 12 after last treatment
3.1 units on a scale
Standard Deviation 2.43
Mean Change From Baseline in Self-rating of Attractiveness
Eyes - month 3 after last treatment
0.4 units on a scale
Standard Deviation 1.62
Mean Change From Baseline in Self-rating of Attractiveness
Eyes - month 12 after last treatment
0.6 units on a scale
Standard Deviation 1.70
Mean Change From Baseline in Self-rating of Attractiveness
Nose - month 3 after last treatment
0.3 units on a scale
Standard Deviation 1.66
Mean Change From Baseline in Self-rating of Attractiveness
Nose - month 12 after last treatment
0.6 units on a scale
Standard Deviation 1.97
Mean Change From Baseline in Self-rating of Attractiveness
Mouth - month 3 after last treatment
0.3 units on a scale
Standard Deviation 1.45
Mean Change From Baseline in Self-rating of Attractiveness
Mouth - month 12 after last treatment
0.6 units on a scale
Standard Deviation 1.44
Mean Change From Baseline in Self-rating of Attractiveness
Entire face - month 3 after last treatment
0.5 units on a scale
Standard Deviation 1.27
Mean Change From Baseline in Self-rating of Attractiveness
Entire face - month 12 after last treatment
0.8 units on a scale
Standard Deviation 1.28

SECONDARY outcome

Timeframe: Month 3 and month 12 after last treatment

Population: Treatment effect population with available data at each time point

Participants answered 3 questions on a 7-point scale that ranged from "a great deal worse" to "a great deal better" (questions 1 and 2) or from "extremely dissatisfied" to "extremely satisfied" (question 3). Question 1: Since the start of the study, how would you rate the fat under your chin right now? Question 2: Since the start of the study, how would you rate the definition between your chin and neck right now? Question 3: How satisfied are you with the treatment you received in this study?

Outcome measures

Outcome measures
Measure
Deoxycholic Acid 2 mg/cm²
n=145 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
Month 12 After Last Treatment
n=130 Participants
Response to Subject Global Questions
Question 1 - a great deal worse
0 participants
0 participants
Response to Subject Global Questions
Question 1 - moderately worse
1 participants
1 participants
Response to Subject Global Questions
Question 1 - a little worse
0 participants
1 participants
Response to Subject Global Questions
Question 1 - about the same
6 participants
7 participants
Response to Subject Global Questions
Question 1 - a little better
22 participants
23 participants
Response to Subject Global Questions
Question 1 - moderately better
48 participants
32 participants
Response to Subject Global Questions
Question 1 - a great deal better
68 participants
66 participants
Response to Subject Global Questions
Question 2 - a great deal worse
0 participants
0 participants
Response to Subject Global Questions
Question 2 - moderately worse
0 participants
1 participants
Response to Subject Global Questions
Question 2 - a little worse
0 participants
0 participants
Response to Subject Global Questions
Question 2 - about the same
5 participants
5 participants
Response to Subject Global Questions
Question 2 - a little better
27 participants
27 participants
Response to Subject Global Questions
Question 2 - moderately better
53 participants
38 participants
Response to Subject Global Questions
Question 2 - a great deal better
60 participants
59 participants
Response to Subject Global Questions
Question 3 - extremely dissatisfied
1 participants
1 participants
Response to Subject Global Questions
Question 3 - moderately dissatisfied
0 participants
1 participants
Response to Subject Global Questions
Question 3 - a little dissatisfied
2 participants
2 participants
Response to Subject Global Questions
Question 3 - neither dissatisfied nor satisfied
5 participants
6 participants
Response to Subject Global Questions
Question 3 - a little satisfied
15 participants
11 participants
Response to Subject Global Questions
Question 3 - moderately satisfied
43 participants
30 participants
Response to Subject Global Questions
Question 3 - extremely satisfied
79 participants
79 participants

SECONDARY outcome

Timeframe: Baseline and month 3 and month 12 after last treatment

Population: Treatment effect population with available data at baseline (164) and at each time point

Submental fat thickness was measured using calipers.

Outcome measures

Outcome measures
Measure
Deoxycholic Acid 2 mg/cm²
n=164 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
Month 12 After Last Treatment
Percent Change From Baseline in Submental Fat Thickness
Month 3 after last treatment (n = 144)
-27.2 percent change
Standard Deviation 21.82
Percent Change From Baseline in Submental Fat Thickness
Month 12 after last treatment (n = 131)
-30.9 percent change
Standard Deviation 20.88

SECONDARY outcome

Timeframe: Baseline and month 3 and month 12 after last treatment

Population: Treatment effect population with available data (indicated by "n")

SMSLG assessment was based on clinical evaluation and palpation of the submental area. The SMSLG scale incorporates 3 features: skin wrinkling, adherence to underlying neck structures (bone and muscle) and redundancy (horizontal and vertical folds). Grade 1 (none): no or minimal superficial wrinkling, skin well apposed to deeper neck structures, no skin redundancy (no skin draping (vertical folds) or skin sagging (horizontal folds)); Grade 2 (mild): mild superficial wrinkling, skin well apposed to deeper neck structures, minimal skin redundancy (slight skin draping and sagging); Grade 3 (moderate): may have mild to moderate superficial wrinkling, skin has mild to moderate separation from deeper neck structures, moderate skin redundancy (moderate skin draping and skin sagging); Grade 4 (severe): mild to marked superficial wrinkling, loose skin separated from deeper neck structures, marked skin redundancy (marked skin draping and sagging).

Outcome measures

Outcome measures
Measure
Deoxycholic Acid 2 mg/cm²
n=165 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
Month 12 After Last Treatment
Change From Baseline in Submental Skin Laxity Grade (SMSLG)
Month 3 after last treatment (n = 144)
-0.3 units on a scale
Standard Deviation 0.58
Change From Baseline in Submental Skin Laxity Grade (SMSLG)
Month 12 after last treatment (n = 131)
-0.3 units on a scale
Standard Deviation 0.63

SECONDARY outcome

Timeframe: Baseline and month 3 after last treatment

Population: Treatment effect population with available data

Each participant was given 2 example line drawings representing each of the 5 submental fat grades (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme) and asked to select the drawing that best represents their current profile. Improvement is any decrease in grade, and worsening is any increase in grade.

Outcome measures

Outcome measures
Measure
Deoxycholic Acid 2 mg/cm²
n=143 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
Month 12 After Last Treatment
Change From Baseline in Line Drawing Assessment
Improved by > 2
27 participants
Change From Baseline in Line Drawing Assessment
Improved by 2
52 participants
Change From Baseline in Line Drawing Assessment
Improved by 1
25 participants
Change From Baseline in Line Drawing Assessment
Unchanged
31 participants
Change From Baseline in Line Drawing Assessment
Worsened by 1
8 participants
Change From Baseline in Line Drawing Assessment
Worsened by 2
0 participants
Change From Baseline in Line Drawing Assessment
Worsened by > 2
0 participants

Adverse Events

Deoxycholic Acid 2 mg/cm²

Serious events: 7 serious events
Other events: 160 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Deoxycholic Acid 2 mg/cm²
n=165 participants at risk
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer
0.61%
1/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer
0.61%
1/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
General disorders
Cardiac death
0.61%
1/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
Infections and infestations
Diverticulitis
0.61%
1/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
Psychiatric disorders
Anxiety
0.61%
1/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
Reproductive system and breast disorders
Cervical polyp
0.61%
1/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
Surgical and medical procedures
Stent placement
0.61%
1/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
Vascular disorders
Arteriosclerosis
0.61%
1/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)

Other adverse events

Other adverse events
Measure
Deoxycholic Acid 2 mg/cm²
n=165 participants at risk
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
General disorders
Injection site hematoma
73.3%
121/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
General disorders
Injection site anesthesia
70.3%
116/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
General disorders
Injection site pain
68.5%
113/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
General disorders
Injection site edema
67.3%
111/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
General disorders
Injection site erythema
50.3%
83/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
General disorders
Injection site induration
37.0%
61/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
General disorders
Injection site swelling
29.7%
49/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
General disorders
Injection site pruritus
21.8%
36/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
General disorders
Injection site nodule
19.4%
32/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
General disorders
Injection site paresthesia
18.8%
31/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
Nervous system disorders
Headache
9.1%
15/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
Investigations
Blood triglycerides increased
7.3%
12/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
Investigations
Blood glucose increased
5.5%
9/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)

Additional Information

Clinical Trial Disclosure

Kythera Biopharmaceuticals, Inc.

Results disclosure agreements

  • Principal investigator is a sponsor employee The clinical study agreement requires that the investigator or institution obtain written consent from Kythera Biopharmaceuticals, Inc. prior to presenting and/or publishing results of this study.
  • Publication restrictions are in place

Restriction type: OTHER